CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure. CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure.

GSK and Sanofi partner up to find Covid-19 vaccine

The two pharmaceutical companies have joined forces to create a vaccine for Covid-19.

UK-based GlaxoSmithKline (GSK) and France-based Sanofi have joined forces to help manufacture a vaccine for Covid-19.

The two pharmaceutical companies have partnered up as combined the pair have the largest vaccine capabilities in the world, with both believing that by working together they create a vaccine for the virus that could be ready for human trials within months.

If successful, the pair’s capacity will allow them to manufacture hundreds of millions of doses that are likely to be required worldwide.

Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology.

This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi's licensed recombinant influenza product in the US.

GSK will contribute its proven pandemic adjuvant technology to the collaboration.

The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

The combination of a protein-based antigen together with an adjuvant, is well-established and used in a number of vaccines available today.

An adjuvant is added to some vaccines to enhance the immune response, and has been shown to create a stronger and longer lasting immunity against infections than the vaccine alone.

It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.

GSK-Sanofi partnership ‘unprecedented’

GSK CEO Emma Walmsley labelled the collaborative effort as ‘unprecedented’.

‘What is not common is you’ve got two of the biggest vaccine manufacturers in the world coming together,’ she added. ‘Both bring significant manufacturing capacity. We believe we’ll be able to make hundreds of millions of doses by the end of next year.’

Walmsley’s counterpart at Sanofi admitted that ‘no one company can go it alone’ in the fight against Covid-19 which has brought about an unparalleled global health crisis.

‘That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus,’ Sanofi CEO Paul Hudson said in a statement.

How to trade stocks with IG

Looking to trade GSK and other stocks? Open a live or demo account with IG and buy (long) or sell (short) the stock using derivatives like CFDs in a few easy steps:

  • Create an IG Trading Account or log in to your existing account

  • Enter ‘GlaxoSmithKline’ in the search bar and select it

  • Choose your position size

  • Click on ‘buy’ or ‘sell’ in the deal ticket

  • Confirm the trade


This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

React to global volatility

Market volatility continues as coronavirus dominates the global agenda. Trade with us to take advantage of:

  • Tight spreads – from just 1 point on major indices, and 2.8 on US crude
  • Guaranteed stops – they’re free to use, and you’ll only pay a small fee if they’re triggered
  • Round-the-clock assistance – our highly-skilled team are on hand to support you

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Friday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.